Emphysema
Also known as: Pulmonary Emphysema, COPD-Emphysema
Emphysema is a chronic, progressive lung disease and a major form of COPD in which the air sacs (alveoli) in the lungs are damaged and enlarged, reducing the surface area for gas exchange. Cigarette smoking is the primary cause, and the resulting shortness of breath worsens over time. While lung damage is irreversible, treatment can slow progression and improve quality of life.
Last updated November 10, 2026
Understanding Emphysema
Emphysema is permanent destruction of the walls of the alveoli, the roughly 300 million tiny air sacs where oxygen crosses into the blood. As the walls break down, small sacs merge into larger, floppier spaces with far less surface area and far less elastic recoil, so air gets in but cannot easily get out. It is one of the two faces of chronic obstructive pulmonary disease, the other being chronic bronchitis, and most people have some of each. About 3.5 to 3.8 million American adults have been told they have emphysema, within a COPD population of 16 million diagnosed and probably as many again undiagnosed; COPD remains a top-five cause of death in the United States, taking about 150,000 lives a year. Cigarette smoking causes 85 to 90 percent of cases, though only about 1 in 4 or 5 long-term smokers develops significant disease, which points to genetic susceptibility. Alpha-1 antitrypsin deficiency, an inherited lack of the protein that shields the lung from its own enzymes, accounts for 1 to 3 percent of cases, often appears before 45, and is thought to be undiagnosed in more than 90 percent of the roughly 100,000 Americans who have it.
The lung is constantly patrolled by neutrophils and macrophages that release elastase and other proteases to clear debris and microbes; alpha-1 antitrypsin and related inhibitors normally hold those enzymes in check. Smoke floods the lung with inflammatory cells, oxidizes and inactivates the inhibitors, and the balance tips toward digestion of the elastin scaffold that gives alveoli their spring. In smokers the damage starts at the center of each lung lobule and in the upper lobes; in alpha-1 deficiency it is more uniform and worst at the bases. Loss of recoil has two consequences people feel. Airways that were held open by surrounding tissue now collapse on breathing out, trapping air, and the chest becomes hyperinflated. During exertion the breathing rate rises faster than the lungs can empty, so each breath starts from a fuller chest with less room to expand, which is why breathlessness on stairs can be severe while resting oxygen levels look normal. Lung function in healthy adults falls about 30 mL of FEV1 a year after 30; in susceptible smokers it falls roughly twice as fast, and every exacerbation steepens the slope. Quitting smoking returns the rate of decline close to normal at any stage, which is the single most important fact about the disease.
Care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, updated yearly. Diagnosis needs spirometry showing a post-bronchodilator FEV1/FVC ratio below 0.70, and GOLD recommends that everyone with COPD be tested once for alpha-1 antitrypsin. Treatment starts with a long-acting bronchodilator, usually a LAMA or a LAMA plus LABA combination, which reduce breathlessness and exacerbations. An inhaled steroid is added for people with repeated exacerbations and a blood eosinophil count of 300 or more; in the 8,509-patient ETHOS trial, triple therapy cut all-cause mortality by about half compared with a dual bronchodilator in frequent exacerbators. Pulmonary rehabilitation, 6 to 12 weeks of supervised exercise and education, is the most effective treatment for breathlessness and quality of life in the evidence base, improving six-minute walk distance by about 44 meters across 65 trials, and after a hospital admission it reduces readmission. Long-term oxygen, at least 15 hours a day, extends life when resting oxygen tension is 55 mmHg or lower, but the 738-patient LOTT trial found no benefit for moderate desaturation. For severe upper-lobe emphysema, lung volume reduction surgery improved survival in a selected subgroup of the 1,218-patient NETT trial, and endobronchial valves now offer a less invasive version: in the LIBERATE trial, 48 percent of valve patients gained at least 15 percent in FEV1 against 17 percent of controls. Azithromycin and roflumilast help frequent exacerbators, and vaccination against influenza, pneumococcus, RSV, COVID-19, pertussis and shingles is standard care.
No supplement rebuilds alveoli, and anything promising to reverse emphysema or clear the lungs is selling something. Two have reasonable evidence for a narrower job. N-acetylcysteine at 1,200 mg a day reduced exacerbations by about 22 percent in a 1,006-patient trial, though it does not change lung function decline. Vitamin D supplementation cut moderate and severe exacerbations by 45 percent in people whose level was below 10 ng/mL, and did nothing for those who were not deficient, so a blood test comes before the bottle. Beetroot juice taken before rehabilitation sessions added about 30 meters to walking distance in a 122-patient trial, a small effect worth knowing about. Creatine, L-carnitine and whey protein have mixed or single-trial evidence for muscle strength in rehabilitation and none for breathing. On the other side of the ledger, antioxidant vitamins A, C and E have not reduced exacerbations or slowed decline, beta-carotene increased lung cancer in smokers in two large trials, and herbal products sold as lung cleansers (mullein, lobelia, oregano oil, eucalyptus inhalations) have no trials in COPD and can provoke bronchospasm. Nothing on this list substitutes for a maintenance inhaler, a rehabilitation program or stopping smoking.
The most common mistake is treating emphysema as a rescue-inhaler disease: using albuterol when breathless and skipping the long-acting inhaler on days that feel fine. Maintenance bronchodilators work by keeping the airways open around the clock and preventing exacerbations, each of which permanently costs lung function; stopping them because symptoms are quiet is like stopping a blood pressure pill because the number looks good. The companion mistake is poor inhaler technique, which studies find in 50 to 80 percent of users, and which can mean a fraction of the dose reaches the lung. Ask to demonstrate your technique at every visit and consider a spacer with a metered-dose inhaler. The second mistake is avoiding exertion because it causes breathlessness. Resting leads to muscle loss, which makes the same task need more oxygen, which makes breathlessness worse, and the spiral ends in a chair; pulmonary rehabilitation exists to break that cycle safely. Finally, learn the signs of an exacerbation, more breathlessness, more sputum or a change in its color for 2 days or more, and have an agreed action plan, because treatment started within 24 hours shortens recovery and reduces hospital admission.
At a Glance
- Common symptoms
- Progressive shortness of breath, especially during physical activity, Chronic cough with or without mucus, Wheezing
- Main treatments
- Smoking cessation (most important intervention), Bronchodilators (short-acting and long-acting inhalers), Inhaled corticosteroids for frequent exacerbations
- Category
- Respiratory · Affects approximately 3.5 million Americans
- See a doctor if
- Shortness of breath is increasing or interfering with daily activities
Symptoms
Causes
- Cigarette smoking (most common cause)
- Long-term exposure to air pollutants, chemical fumes, or dust
- Alpha-1 antitrypsin deficiency (genetic cause)
- Destruction of alveolar walls by protease enzymes and oxidative stress
Risk Factors
- Current or former cigarette smoking
- Age 40 and older
- Occupational exposure to dust, fumes, or chemicals
- Alpha-1 antitrypsin deficiency
- Secondhand smoke exposure
Diagnosis
- Pulmonary function tests (spirometry) showing irreversible airflow obstruction
- Chest X-ray showing hyperinflated lungs
- High-resolution CT scan for detailed assessment
- Arterial blood gas analysis for advanced disease
- Alpha-1 antitrypsin level testing
Treatment
- Smoking cessation (most important intervention)
- Bronchodilators (short-acting and long-acting inhalers)
- Inhaled corticosteroids for frequent exacerbations
- Pulmonary rehabilitation program
- Supplemental oxygen therapy for advanced disease
- Lung volume reduction surgery or transplant for severe cases
Natural remedies for emphysema: what the evidence says
Ranked by the strength of human evidence for emphysema specifically. These sit alongside medical care, not in place of it.
N-Acetylcysteine
Moderate evidenceNAC thins mucus and replenishes glutathione in a lung under oxidative attack. In the 1-year PANTHEON trial, 1,006 people with moderate to severe COPD who took 600 mg twice daily had 1.16 exacerbations a year against 1.35 on placebo, a 22 percent reduction, with the benefit concentrated in those with GOLD stage 2 disease. The earlier BRONCUS trial of 600 mg once daily found no effect on FEV1 decline or exacerbations, and a Cochrane review concluded that doses of 1,200 mg a day or more are needed. It does not improve lung function.
- Studied dose
- 600 mg twice daily (1,200 mg/day) by mouth, taken long term; the trials ran 1 to 3 years.
- Cautions
- Can cause nausea, heartburn and, rarely, bronchospasm when inhaled; take with food. Effervescent forms carry sodium, and NAC may slightly enhance the effect of nitroglycerin and warfarin. Stop if a rash develops.
Vitamin D
Moderate evidenceLow vitamin D is common in COPD and tracks with severity. A 2019 individual-participant meta-analysis in Thorax pooled 3 randomized trials (469 people) and found vitamin D reduced the rate of moderate or severe exacerbations by 45 percent in those with a baseline level below 10 ng/mL, with no effect in people above that level. A later 2023 Cochrane review reached the same conclusion: benefit is confined to the deficient. It does not change lung function or breathlessness.
- Studied dose
- Test first. For a level below 20 ng/mL, 1,000 to 4,000 IU vitamin D3 daily or an equivalent weekly dose, rechecked after 3 months; the trials used daily or monthly dosing rather than large annual boluses.
- Cautions
- Avoid high doses in sarcoidosis, lymphoma or hypercalcemia. Thiazide diuretics raise calcium when combined with vitamin D, and oral steroids given for exacerbations increase bone loss, so pair vitamin D with adequate calcium and a bone density check.
Beetroot (Dietary Nitrate)
Preliminary evidenceNitrate in beetroot juice is converted to nitric oxide, which widens blood vessels and makes muscle more efficient. In the ON-EPIC trial, 122 people with COPD drank concentrated beetroot juice (about 12.9 mmol nitrate) or a nitrate-depleted placebo before each session of an 8-week pulmonary rehabilitation program; the beetroot group improved their 6-minute walk distance by about 30 meters more than placebo and had lower systolic blood pressure. Smaller earlier trials were mixed, and there is no evidence for taking it outside an exercise program.
- Studied dose
- 70 ml of concentrated beetroot juice (roughly 400 mg or 6 to 13 mmol nitrate) 2 to 3 hours before exercise sessions.
- Cautions
- Turns urine and stool red, which is harmless. Nitrate lowers blood pressure, so take care with antihypertensives and avoid combining with nitroglycerin or sildenafil-type drugs. Antibacterial mouthwash blocks the conversion to nitrite and cancels the effect.
Creatine
Preliminary evidenceLeg muscle wasting drives disability in emphysema, and creatine is the best-studied supplement for muscle. A 38-person trial found creatine during pulmonary rehabilitation increased fat-free mass, leg strength and health status more than placebo, but a larger 100-person trial found no added benefit over rehabilitation alone, and a 2017 meta-analysis of 5 trials (222 people) concluded it does not improve exercise capacity or quality of life. It is reasonable only as an adjunct to resistance training in someone who is losing muscle.
- Studied dose
- 3 to 5 g creatine monohydrate daily with food during a strength-training program; a loading phase is unnecessary.
- Cautions
- Causes water retention of 1 to 2 kg in the first weeks. Ask first if kidney function is reduced, and drink enough fluid; it has no effect on breathing and should not replace rehabilitation.
What matters day to day
- Stop smoking with help, not willpower alone: combining varenicline or nicotine replacement with counseling triples quit rates, and in the 5,887-person Lung Health Study, quitters lost lung function at half the rate of those who kept smoking.
- Ask for pulmonary rehabilitation and finish the program: 6 to 12 weeks of supervised exercise improves walking distance by about 44 meters, cuts breathlessness and, after a hospital admission, reduces readmission more than any inhaler.
- Walk every day, using pursed-lip breathing on the hard parts: breathing in through the nose and out slowly through pursed lips for twice as long keeps collapsing airways open on exhalation and reduces air trapping, so the next breath has more room.
- Eat enough protein and calories if your weight is falling: a BMI under 21 or unintended weight loss doubles mortality in COPD, and small frequent meals with 1.2 to 1.5 g of protein per kg of body weight a day help preserve the breathing muscles.
- Keep vaccines current: influenza vaccination cuts COPD exacerbations by roughly a third in trials, and pneumococcal, RSV, COVID-19 and pertussis vaccines each target an infection that commonly tips emphysema into hospital.
- Check the air quality index and stay indoors with windows shut when it is above 100: fine particulate pollution and wildfire smoke raise COPD emergency visits within a day or two, and an indoor HEPA filter lowers exposure.
Prevention
- Do not smoke, and quit if you currently smoke
- Avoid exposure to secondhand smoke and air pollutants
- Use protective equipment in occupations with dust or chemical exposure
- Get tested for alpha-1 antitrypsin deficiency if you have a family history
When to See a Doctor
- Shortness of breath is increasing or interfering with daily activities
- Lips or fingernails turn blue or gray (cyanosis)
- You experience a rapid heartbeat with breathlessness
- Mental alertness decreases during breathing difficulties
Frequently Asked Questions
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report (2025)
- Anthonisen NR, Connett JE, Kiley JP, et al.. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA (1994)
- McCarthy B, Casey D, Devane D, et al.. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (2015)
- Rabe KF, Martinez FJ, Ferguson GT, et al.. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine (2020)
- Fishman A, Martinez F, Naunheim K, et al.; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. New England Journal of Medicine (2003)
- Criner GJ, Sue R, Wright S, et al.. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). American Journal of Respiratory and Critical Care Medicine (2018)
- Zheng JP, Wen FQ, Bai CX, et al.. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine (2014)
- Jolliffe DA, Greenberg L, Hooper RL, et al.. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax (2019)
- Pavitt MJ, Tanner RJ, Lewis A, et al.. Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study. Thorax (2020)
- MedlinePlus, National Library of Medicine. Emphysema (2024)View source
Related Conditions
Evidence-graded guides
Have questions about Emphysema?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.